Navigation Links
StemCyte Awarded $488,950 for Advanced Therapeutic Applications of Umbilical Cord Blood Stem Cells from the Qualifying Therapeutic Discovery Project (QTDP)
Date:11/11/2010

COVINA, Calif., Nov. 11, 2010 /PRNewswire/ -- StemCyte, Inc., one of the world's preeminent umbilical cord blood (UCB) banks and biotherapy companies, is proud to announce that the Company has been awarded two cash grants totaling $488,950 under the U.S. Internal Revenue Service's Qualifying Therapeutic Discovery Project (QTDP) program designed to support biomedical research by firms with fewer than 250 employees.

The Patient Protection and Affordable Care Act of 2010 (PPACA) created the QTDP program as a means to support qualified research and development projects that show significant potential to produce new and cost-saving therapies, support job growth and increase U.S. competitiveness.  Following a competitive application process, StemCyte was awarded two grants for advance therapies using UCB stem cells for the potential treatment of chronic spinal cord injury and chronic stroke.

"We are very pleased to have been awarded these grants and believe it reflects positively on the Advanced Therapeutic applications of cord blood stem cells that we continue to pursue," said Ken Giacin, StemCyte, Inc's Chairman and CEO.  "These awards reaffirm our belief that our UCB-related research has great potential for saving and improving lives."

The Internal Revenue Service issued the QTDP awards and will administer the program.  The QTDP program is designed to provide grants and tax credits to qualified biotechnology companies with fewer than 250 employees that demonstrate the potential to develop new therapies to treat chronic condition, address unmet medical needs, reduce health care costs, and advance the goal of curing cancer within 30 years.

About StemCyte, Inc.

Located in the US, India and Taiwan, StemCyte has established one of the largest, most racially diverse, and highest quality cord blood stem cell banks in the world.  StemCyte has supplied over 1,300 cord blood products for over 40 life-threatening diseases to over 200 leading worldwide transplant centers.  StemCyte is actively involved in the development of new umbilical cord blood-based cell therapies.  They are supporting the largest clinical study for using unrelated cord blood transplantation for thalassemia, one of the most common genetic diseases in the world, as well as supporting trials investigating regenerative spinal cord therapies.  They are the only for-profit company contracted by the US Department of HHS to establish a public National Cord Blood Inventory for unrelated transplant units.  Its headquarters are located in Covina, Ca. and Ewing, NJ.  To learn more visit www.StemCyte.com.


'/>"/>
SOURCE StemCyte, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. 7-Time Olympic Medalist Shannon Miller Endorses StemCyte
2. Functional Nutriments Awarded Federal Grant to Apply Its Dog Nutraceutical Research to Human Cancer
3. U.S. Government Grants Awarded for Further Development of Adult Stem Cell Products
4. Catapult Systems Awarded SharePoint 2010 and FAST Intranet Project
5. NOVAVAX Awarded Nearly $1 Million in Grants from IRS Under Qualifying Therapeutic Discovery Project
6. Lentigen Awarded $1.2 Million by U.S. Government Under the Qualifying Therapeutic Discovery Project
7. Regado Biosciences Awarded Three Grants from the Federal Government to Advance Research of Lead Programs
8. Sangamo BioSciences Awarded Grants for the Development of Four ZFP Therapeutic® Programs
9. Omeros Corporation Awarded $1.7 Million in Grants Under the Qualifying Therapeutic Discovery Project Program
10. Federal nanotechnology renewal grant awarded to ASU faculty
11. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Regular discussions on a range of subjects ... the two entities said Poloz. Speaking at a ... , he pointed to the country,s inflation target, which ... "In certain areas ... have common economic goals, why not sit down and address ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... Md. , June 23, 2016 A person ... from the crime scene to track the criminal down. ... the U.S. Food and Drug Administration (FDA) uses DNA evidence ... Sound far-fetched? It,s not. The FDA ... sequencing to support investigations of foodborne illnesses. Put as simply ...
(Date:6/23/2016)... NEW YORK , June, 23, 2016  The ... students to envision new ways to harness living systems ... of Modern Art (MoMA) in New York ... more than 130 participating students, showcased projects at MoMA,s ... included Paola Antonelli , MoMA,s senior curator of ...
Breaking Biology Technology:
(Date:5/24/2016)... facilitates superior patient care by providing unparalleled technology to leaders of the medical imaging ... product recently added to the range of products distributed by Ampronix. Photo ... ... ... News ...
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... , April 28, 2016 Infosys ... (NYSE: INFY ), and Samsung SDS, a global ... that will provide end customers with a more secure, fast ...      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... but it also plays a fundamental part in enabling and ...
Breaking Biology News(10 mins):